ClinicalTrials.gg
TerminatedNCT06572839Updated May 28, 2026

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

An interventional study of Amnio-Maxx in Diabetic Foot Ulcer, sponsored by Capsicure, LLC. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Capsicure, LLC · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Ended after interim analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
144th of 322
74 · median 60
Started
2024
with 32 others
No phase
186 of 381
38 open now
Registered
332nd of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 144th largest by enrollment of the 322 interventional ones that give a count, is one of 33 that started in 2024, is one of 186 with no phase, and was the 332nd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers

Read the detailed description

This is a multicenter randomized open-label clinical study in patients with Wagner grade 1 and 2 DFUs. Diabetic patients presenting with chronic nonhealing ulcers will be screened for eligibility. At least 50% of the eligible population will be drawn from patients ≥ 65 years of age. All patients will complete a 2-week run-in period prior to treatment allocation to Amnio-Maxx and standard of care (SOC) or SOC alone. Patients will be seen at weekly intervals (± 3 days) for the 12 weeks treatment period. If additional dressing changes are required between the scheduled visits, the occurrence of these visits will be recorded. Primary efficacy endpoints include percentage change in ulcer size at 12 weeks along with the proportion of participants achieving complete wound closure. Additionally, pain and safety will be assessed as secondary endpoints.

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • chronic ulcers
  • wound care
  • Dual Layer Amnion Patch
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects are 18 years of age or older. At least 50% of the enrolled population must be > 65 years of age.
  2. Subject history of Type I or Type II Diabetes Mellitus requiring oral glycemic control and/or insulin replacement therapy.
  3. Subjects with the following ulcer:

    A. Presence of a DFU Wagner 1 or 2 grade at the first screening visit on any aspect of the foot, provided it is at or below the aspect of the medial malleolus. [NOTE: If two or more DFUs are present with the same grade, the index ulcer is the largest ulcer and the only one evaluated in the study. Index ulcer must be more than 5 cm distant apart.

    B. A DFU is present for greater than 4 weeks (documented in the medical record) but less than 12 months duration if being treated with active SOC.

  4. Objectively, less than 20% healing in the two-week screening period prior to randomization.
  5. Study ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 post-debridement at first treatment visit
  6. Index ulcer and/or index ulcer limb may have had prior infection, but infection(s) must be adequately treated and controlled as defined by IDSA Guidelines Grade level 1.
  7. The subject is able and willing to follow the protocol requirements.
  8. Subject has signed .
  9. Adequate circulation to the affected foot as demonstrated by a dorsum transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg; an ABI between 0.7 and ≤ 1.3, or TBI of >6 within 3 months of the first Screening Visit.
  10. Negative pregnancy test for females of (e.g., not post- menopausal for at least one year or surgically sterile). Females of childbearing potential must be willing to use acceptable methods of (birth control pills, barriers, or abstinence) starting at Screening and continuing through the duration of their study participation.
  11. The index ulcer has been offloaded with protocol defined offloading device throughout the study run-in period for at least 14 days prior to randomization (Run- in period defined as Screening through TV1/Randomization).
  12. The index ulcer has a clean base and free of necrotic debris at time of placement of treatment product.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a documented of \< 1 year.
  2. Index ulcer has been present for >1 year.
  3. Patient does not have adequate 2-week historical data demonstrating \< 20% area reduction.
  4. Subject is unable to comply with offloading device.
  5. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence to medical treatment.
  6. Subject has ulcers that are completely necrotic or fibrotic tissue.
  7. Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia.
  8. Subject currently being treated for an active malignant disease or subjects with history of within the ulcer.
  9. The Subject has other concurrent conditions that in the opinion of the Principal Investigator may compromise subject safety.
  10. Known to amniotic tissue membranes or known allergies to any of the Amnio-Maxx components.
  11. Concurrent participation in another clinical trial that involves an drug or device that would interfere with this study.
  12. Index ulcer has reduced in area by 20% or more after 2 weeks of SOC from the first screening visit (S1) to the TV1/randomization visit.
  13. Subject is pregnant or breastfeeding.
  14. Subjects with a history of more than two weeks treatment with (including systemic >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 30 days prior to randomization visit or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  15. Index ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days preceding the first treatment visit.
  16. Affected extremity requiring hyperbaric oxygen during the trial or within 2 weeks of screening treatment visit 1.
  17. Presence of diabetes with poor metabolic control as documented with an ≥12.0 within 30 days of randomization (TV1).
  18. Index ulcer and/or index limb with presence of, gangrene or unstable ischemia at screening (SV1).
  19. Revascularization surgery on the lower extremity on which the index ulcer is located within 30 days of Screening Visit (SV1).
  20. Index ulcer in the opinion of the Principal Investigator, is suspicious for cancer and should undergo an ulcer to rule out a neoplasm of the ulcer.
  21. Any finding, in the judgment of the Principal Investigator, that would place the subject at health risk, impact the study, or affect the completion of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • No intervention
    No intervention: Standard of Care

    Debridement, offloading, and proper moisture balance dressings

  • Experimental
    Amnio-Maxx as an addition to standard of care

    Device exposure is estimated to be a maximum of 12 weeks

    Other: Amnio-Maxx

Interventions

  • OtherAmnio-Maxx

    Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.

    Also known as: Amnio-Maxx Dual Layer Amnion Allograft

06

What researchers measure

Primary outcomes

  1. Wound Closure Assessment Verified with Independent Adjudication

    To demonstrate change in healing rates of chronic wounds (diabetic foot ulcers), unresponsive to standard therapy.

    Time frame: 12 weeks

  2. Percentage Area Reduction verified with Independent Adjudication

    To demonstrate change in healing rates of chronic wounds (diabetic foot ulcers), unresponsive to standard therapy.

    Time frame: 12 weeks

Secondary outcomes

  1. Chage of Subjects Pain Levels

    Subject pain assessed through the Numeric Pain Rating Scale on a weekly basis throughout the study

    Time frame: 12 weeks

  2. Change in Adverse Events

    Change in Adverse Events estimated from the observed data through physician reporting

    Time frame: 12 weeks

07

Study locations

12 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • North Park Podiatry
    San Diego, California 92104, United States
  • Solutions Medical Research
    Coral Gables, Florida 33134, United States
  • Evolution Research Center
    Hialeah, Florida 33012, United States
  • Symphony Research
    Jacksonville, Florida 32257, United States
  • Quality Care Clinical Research
    Miami, Florida 33142, United States
  • Medcentris
    Hammond, Louisiana 70403, United States
  • Curalta Clinical Trials
    Oradell, New Jersey 07649, United States
  • Suffolk Foot and Ankle
    East Patchogue, New York 11772, United States
  • PA Foot and Ankle Associates
    Allentown, Pennsylvania 18104, United States
  • Stride Clinical Research
    Houston, Texas 77027, United States
  • Ten20 Medical
    Sunnyvale, Texas 75182, United States
08

References and documents

Individual participant data

Plan to share: No — Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor. Any investigator involved with this study is obligated to provide the sponsor with complete test results and all data derived from the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in May 2026, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 27, 2024
StartActual
Oct 25, 2024
Primary completionActual
May 1, 2026
CompletionActual
May 1, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06572839
Lead sponsor
Capsicure, LLC
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Oct 25, 2024
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
May 28, 2026

Study contacts

Windy Cole, DPM
principal investigator · Capsicure, LLC
Marissa Docter, RN, BSN, MD
study director · Capsicure, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion